<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30103560</article-id>
<article-id pub-id-type="pmc">6121554</article-id>
<article-id pub-id-type="doi">10.3390/ijms19082373</article-id>
<article-id pub-id-type="publisher-id">ijms-19-02373</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Salisbury</surname>
<given-names>Travis B</given-names>
</name>
<xref ref-type="corresp" rid="c1-ijms-19-02373">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arthur</surname>
<given-names>Subha</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af1-ijms-19-02373">Departments of Biomedical Sciences and Clinical &amp; Translational Science, Joan C. Edwards School of Medicine, Marshall University, 1 John Marshall Drive, Huntington, WV 25755, USA; <email>arthursu@marshall.edu</email></aff>
<author-notes>
<corresp id="c1-ijms-19-02373"><label>*</label>Correspondence: <email>salisburyt@marshall.edu</email>; Tel.: +1-304-696-7314; Fax: +1-304-696-7391</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2018</year>
</pub-date>
<volume>19</volume>
<issue>8</issue>
<elocation-id>2373</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>7</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 by the authors.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The progression of cancer is associated with increases in amino acid uptake by cancer cells. Upon their entry into cells through specific transporters, exogenous amino acids are used to synthesize proteins, nucleic acids and lipids and to generate ATP. The essential amino acid leucine is also important for maintaining cancer-associated signaling pathways. By upregulating amino acid transporters, cancer cells gain greater access to exogenous amino acids to support chronic proliferation, maintain metabolic pathways, and to enhance certain signal transduction pathways. Suppressing cancer growth by targeting amino acid transporters will require an in-depth understanding of how cancer cells acquire amino acids, in particular, the transporters involved and which cancer pathways are most sensitive to amino acid deprivation. L-Type Amino Acid Transporter 1 (LAT1) mediates the uptake of essential amino acids and its expression is upregulated during the progression of several cancers. We will review the upstream regulators of LAT1 and the downstream effects caused by the overexpression of LAT1 in cancer cells.</p>
</abstract>
<kwd-group>
<kwd>L-Type Amino Acid Transporter 1 (LAT1)</kwd>
<kwd>SLC7A5</kwd>
<kwd>mTOR</kwd>
<kwd>leucine</kwd>
<kwd>cancer</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-19-02373">
<title>1. Introduction: System L Transporters</title>
<p>The synthesis of biomass prior to cell proliferation is heavily dependent on the acquisition of exogenous amino acids that, upon being transported into cells, are used to synthesize proteins, nucleic acids, lipids, and ATP [<xref ref-type="bibr" rid="B1-ijms-19-02373">1</xref>]. The transporters that mediate the uptake of exogenous amino acids into cells are commonly upregulated on cancer cells compared with normal cells, and the robust acquisition of amino acids by cancer cells plays a critical role in cancer progression [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. Many cancer cells rely on system L transporters to acquire essential amino acids [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. The system L transporter family consists for four members: SLC7A5 (also called LAT1), SLC7A8 (also called LAT2), SLC43A1 (also called LAT3), and SLC43A2 (also called LAT4) [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. The LAT transporters mediate the uptake of branch-chained and aromatic amino acids through a sodium-independent mechanism [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. LAT1 and LAT2 are obligatory amino acid exchangers, and LAT3 and LAT4 mediate facilitated amino acid diffusion [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. LAT1 and LAT2 transport leucine, isoleucine, valine, phenylalanine, methionine, tyrosine, histidine, and tryptophan into cells [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. Leucine, isoleucine, valine, phenylalanine, and methionine can also be transported into cells by LAT3 and LAT4 [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>].</p>
<p>In this review, we will focus on the regulation and function of LAT1 in cancer because its role in cancer is broader than the other three LAT transporters [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. Increasing the uptake of leucine into cells is the most effective way that LAT1 promotes the activity of Mechanistic Target of Rapamycin Kinase Complex 1 (mTORC1). LAT1 not only supports mTORC1 activity, it also reinforces MYC and EZH2 signaling in cancer cells. We will review these LAT1-supported downstream effects. Maintaining a high expression and activity of LAT1 in cancer requires a large supporting cast of proteins consisting of a chaperone protein, glutamine transporters, and upstream regulators of LAT1 expression. We will review these different aspects of LAT1 regulation in cancer. Please see <xref ref-type="table" rid="ijms-19-02373-t001">Table 1</xref> for a “summative” glance of the upstream regulators of LAT1 and the downstream effects of LAT1 in cancer (<xref ref-type="table" rid="ijms-19-02373-t001">Table 1</xref>).</p>
</sec>
<sec id="sec2-ijms-19-02373">
<title>2. LAT1 Promotes mTORC1 Activity</title>
<p>Nutrient and growth factor pathways regulate the cellular metabolism and protein synthesis by regulating the activity of mTORC1 [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. Aberrant mTORC1 activation is common in cancer, and mTORC1 signaling promotes cancer progression by stimulating pathways that in turn support cancer cell growth, proliferation and resistance to apoptosis [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. In regards to amino acids, leucine is the most effective activator of mTORC1 [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. Leucine stimulates the translocation of mTORC1 to the surface of the lysosome, which is the site of mTORC1 activation [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. The processes by which leucine regulates mTORC1 is complex because there are two leucine binding proteins and four Rag Guanosine triphosphate (GTP) binding proteins (Rag GTPases) involved [<xref ref-type="bibr" rid="B13-ijms-19-02373">13</xref>,<xref ref-type="bibr" rid="B14-ijms-19-02373">14</xref>,<xref ref-type="bibr" rid="B15-ijms-19-02373">15</xref>,<xref ref-type="bibr" rid="B16-ijms-19-02373">16</xref>]. Although there are four Rag GTPases (RagA, RagB, RagC, and RagD), RagB/RagD heterodimers are the most effective at activating mTORC1 [<xref ref-type="bibr" rid="B14-ijms-19-02373">14</xref>]. The two leucine-binding proteins that promote the activation of mTORC1 work through different mechanisms. Leucyl-tRNA synthetase (LRS) upon binding to leucine triggers the hydrolysis of RagD-GTP to RagD-GDP, and RagD-GDP is the form that activates mTORC1 [<xref ref-type="bibr" rid="B14-ijms-19-02373">14</xref>,<xref ref-type="bibr" rid="B16-ijms-19-02373">16</xref>]. The binding of leucine to Sestrin2 disrupts the binding of Sestrin2 to GATOR2, which in turn allows GATOR2 to proceed with activating mTORC1 [<xref ref-type="bibr" rid="B13-ijms-19-02373">13</xref>]. These leucine-triggered molecular events allow lysosome bound mTORC1 to carry out its signaling in response to growth factor (such as insulin or IGF1) signaling [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. The tuberous sclerosis complex (TSC) (composed of TSC1 and TSC2) and Ras Homolog Enriched In Brain (RHEB) are insulin/IGF1 responsive regulators of mTORC1 [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. The TSC complex promotes the GTPase activity of RHEB and inhibiting TSC activity results in GTP-loaded RHEB [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. Insulin/IGF1-stimulated increases in PI3K/AKT signaling inhibits the TSC complex, leading to a subsequent increase in GTP-loaded RHEB and the activation of mTORC1 [<xref ref-type="bibr" rid="B12-ijms-19-02373">12</xref>]. Consequently, LAT1 by mediating cellular uptake of exogenous leucine, supports and sustains mTORC1 activation in cancer cells.</p>
<p>The findings of a recent report indicate that LAT1 not only associates with the cell membrane, but it also mediates the transfer of leucine into the lysosome [<xref ref-type="bibr" rid="B17-ijms-19-02373">17</xref>]. This requires LAT1 to be recruited to the lysosomal membrane by lysosomal-associated transmembrane protein 4b (LAPTM4b) [<xref ref-type="bibr" rid="B17-ijms-19-02373">17</xref>]. The transfer of leucine into the lysosome mediates the activation of lysosomal membrane H<sup>+</sup> ATPase (V-ATPase) [<xref ref-type="bibr" rid="B18-ijms-19-02373">18</xref>]. V-ATPase is an additional part of the mTORC1 activating complex on the surface of the lysosome [<xref ref-type="bibr" rid="B18-ijms-19-02373">18</xref>]. Results supporting a role for LAPTM4b in this new pathway found that its silencing reduces LAT1 association with the lysosomal membrane, decreases the uptake of leucine into the lysosome and leads to the dephosphorylation of mTORC1 target proteins [<xref ref-type="bibr" rid="B17-ijms-19-02373">17</xref>]. The majority of these results came from studies conducted in Hela cells, and the role of LAPTM4b for mTORC1 activity was confirmed in MDA-MB-231 (breast) or HEPG2 (liver) cancer cells [<xref ref-type="bibr" rid="B17-ijms-19-02373">17</xref>]. In addition, LAPTM4b is overexpressed in breast cancers compared with normal breast tissue, and it is more highly expressed in more advanced cancers, indicating that it is associated with breast cancer progression [<xref ref-type="bibr" rid="B19-ijms-19-02373">19</xref>,<xref ref-type="bibr" rid="B20-ijms-19-02373">20</xref>].</p>
</sec>
<sec id="sec3-ijms-19-02373">
<title>3. Interactions between CD98 and LAT1</title>
<p>LAT1 transports amino acids as a complex composed of LAT1 covalently bound to 4F2 Heavy Chain Antigen (also called CD98 and official gene name: <italic>SLC3A2</italic>) [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. CD98 promotes LAT1 protein stability and mediates the translocation of LAT1 to the cell membrane [<xref ref-type="bibr" rid="B2-ijms-19-02373">2</xref>]. Deciphering the role of CD98 in cancer is complicated because its effects could be due to enhancing amino acid signaling or integrin signaling [<xref ref-type="bibr" rid="B21-ijms-19-02373">21</xref>]. Cormerais et al. (2016) approached this question by comparing LAT1 effects with CD98 effects in LS1747 colon cancer cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Considering the multifunctional role of CD98 in cancer, the CD98 null phenotype should be more severe than the LAT1 null phenotype. Silencing LAT1, however, was more impactful than silencing CD98 [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. There were consequences associated with silencing CD98 in LS1747 cells. For instance, the leucine uptake by CD98 null cells was reduced (by 90%) compared with the control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. However, the reductions in the leucine uptake due to silencing CD98 did not correlate with decreases in cell proliferation [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Silencing CD98 in LS1747 cells did not produce smaller tumors in mice compared with the size of the control tumors [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. This was in stark contrast to the LAT1 null LS1747 cells. Silencing LAT1 in LS1747 cells completely suppressed (by 100%) the uptake of leucine into cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. This result correlated with LAT1 null LS1747 cells not being able to proliferate as rapidly as control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. LAT1 null LS174T cells produced smaller tumors in mice compared with control tumors [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>].</p>
<p>The phosphorylation status of mTORC1 target proteins in LS1747 cells was evaluated in response to silencing LAT1 or CD98 [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. The phosphorylation of S6K and p70 SK6 kinase was lower in LAT1 null cells compared with the control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Conversely, the phosphorylation status of mTORC1 substrates in CD98 null cells was similar to that observed in the control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Based on these findings, the activity of mTORC1 is dependent on LAT1, but not CD98, in LS1747 cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Increases in the phosphorylation of general control nonderepressible 2 (GCN2) and the accumulation of ATF4 protein are hallmark responses of amino acid stress, and both signals were induced in LAT1 null cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. On the contrary, silencing CD98 did not affect the status of GCN2 or ATF4 compared with the control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. When taken together, finding that CD98 null cells (LS1747) maintain mTORC1 and are not amino acid-deprived is surprising, given that their leucine uptake capability was reduced by 90% compared with the control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. The remaining 10% leucine uptake capability in CD98 null cells is due to residual LAT1 activity because blocking LAT1 activity with BCH or JPH203 eliminated (100%) the leucine uptake by CD98 null cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. JPH203 is also more effective at inhibiting the proliferation of CD98 null cells compared with the control cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Thus, CD98 null cells are more vulnerable to perturbation of LAT1 activity, presumably because knocking out CD98 reduced (by 90%) their capacity for leucine uptake [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. The remaining 10% of LAT1 activity in CD98 null cells is interesting because it brings the question as to how LAT1 is transporting amino acids in the absence of CD98. Perhaps there are two LAT1 chaperone proteins in LS1747 cells.</p>
</sec>
<sec id="sec4-ijms-19-02373">
<title>4. EZH2 and LAT1 Mutual Relationship</title>
<p>The findings of a recent report have established reciprocal inductive interactions between LAT1 and the epigenetic regulator Enhancer of Zeste Homolog 2 (EZH2) in lung cancer cells [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. Sorting cells by CD98 identified two populations of lung cancer cells, one population expressed high levels of CD98 and LAT1 and the other population expressed low levels of CD98 and LAT1 [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. Cells that expressed higher levels of CD98/LAT1 exhibited a more aggressive tumor phenotype compared with cells that expressed low levels of CD98/LAT1 [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. The CD98/LAT1 positive cells also produced larger tumors in mice compared with tumors that expressed low levels of CD98/LAT1 [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. A metabolomic analysis identified that the levels of <italic>S</italic>-adenosylmethionine (SAM) were correlated with the expression of CD98/LAT1 [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. SAM is the methyl donor used by EZH2 to tri-methylate lysine 9 on histone H3 (H3K9me3) [<xref ref-type="bibr" rid="B22-ijms-19-02373">22</xref>]. This particular histone marker reduces tumor suppressor genes, and is one mechanism by which EZH2 is postulated to promote cancer progression [<xref ref-type="bibr" rid="B22-ijms-19-02373">22</xref>]. Accordingly, H3K9me3 levels in the total cell extract were higher in CD98/LAT1 high cells than CD98/LAT1 low cells [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. Whether specific EZH2 target genes were repressed in CD98/LAT1 high cells compared to CD98/LAT1 low cells was not reported, and could be a topic for future study.</p>
<p>The authors provided several lines of additional evidence for a link between EZH2 and LAT1 in lung cancer. Silencing and pharmacological inhibition of EZH2 in NCI-H1299 lung cancer cells caused reductions in LAT1 mRNA and protein [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. The mechanism by which EZH2 increases LAT1 is complex because the <italic>LAT1 gene</italic> is not a direct EZH2 target gene [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. In the context of retinoic acid signaling, EZH2 disinhibited LAT1 expression by reducing the expression of retinoid X receptor alpha (RXRA) [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. The expression of LAT1 and EZH2 were also linked with more undifferentiated cancer. Promoting the differentiation of lung cancer cells by culturing them as pulmospheres caused decreases in the LAT1, CD98, and EZH2 protein levels [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. Expressing SV40 large T-antigen in normal lung epithelial cells causes them to become cancer cells, and this correlated with the upregulation of LAT1, CD98 and EZH2 protein [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. Within lung tumor samples, LAT1 and EZH2 were co-expressed in cancer cells that were more undifferentiated and highly proliferative compared with not being expressed in the adjacent stromal tissue [<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]. Thus, LAT1 and EZH2 appear to be functionally linked with a more aggressive lung cancer phenotype. This finding has provided new insight into the regulation and function of LAT1 in cancer and inhibiting LAT1 could be a new way to suppress the cancer-promoting effects of EZH2.</p>
</sec>
<sec id="sec5-ijms-19-02373">
<title>5. LAT1 and MYC Feedforward Mechanism</title>
<p>The findings of a recent study identified that LAT1 and MYC amplify each other’s expression and activity in Burkitt’s lymphoma and neuroblastoma cells [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. The authors showed that MYC induces LAT1 and LAT3, both targets of MYC, and silencing MYC decreases the level of LAT1 and LAT3 mRNA and protein [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Knocking down LAT1 or LAT3 expression reduced the uptake of leucine and phenylalanine into cells [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Accordingly, silencing MYC also reduced the uptake of leucine and phenylalanine into cells [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Decreases in LAT1 and LAT3 in MYC knockdown cells prevented leucine-stimulated increases in mTORC1 activity, presumably because leucine could not enter MYC null cells [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Silencing LAT1 inhibits the proliferation of Burkitt’s lymphoma cells (Daudi) and neuroblastoma cells (BE-2C), indicating that LAT1 induction by MYC is tied with cancer cell proliferation [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. LAT1 null neuroblastoma tumors were smaller than control tumors in mice, indicating that LAT1 promotes the progression of this cancer [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Ectopic expression of LAT1 in neuroblastoma cells also produced larger tumors in mice compared with control tumors [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>].</p>
<p>Western blot analysis of LAT1 null Burkitt’s lymphoma cells and neuroblastoma cells identified a reduction in MYC protein; however, the levels of MYC mRNA were not reduced [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Considering that amino acid uptake is reduced in LAT1 null cells, the observed reductions in MYC protein could reflect a defect in MYC translation due to a shortage of amino acids. Accordingly, a defect in MYC translation was confirmed in Burkitt’s lymphoma cells and neuroblastoma cells that were null for LAT1 compared with the control cells [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. A defect in MYC translation could lead to global gene expression changes because MYC is the primary transcription factor in cancer cells. Consequently, gene expression profiling experiments were conducted in LAT1 null and MYC null cells (Burkitt’s lymphoma cells). The results indicated that the majority of gene expression changes caused by the silencing of LAT1 were likely due to the MYC protein being reduced in LAT1 null cells [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Specifically, silencing LAT1 changed the expression of 1120 genes [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Of these 1120 genes, 689 were MYC regulated genes [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Silencing MYC changed the expression of 3948 genes [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. The RT-PCR analysis confirmed the downregulation of 24 MYC target genes in LAT1 knockdown cells that play roles in metabolism, translation, and growth [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>].</p>
<p>Oncogenic MYC influences cancer cell metabolism by increasing the expression of glucose and glutamine transporters and promoting glucose and glutamine metabolism [<xref ref-type="bibr" rid="B23-ijms-19-02373">23</xref>]. Considering that MYC translation required LAT1, the effect of LAT1 on MYC-regulated metabolic pathways was evaluated. Silencing LAT1, depriving cells of essential amino acids, or treating cells with the LAT1 inhibitor BCH (2-aminobicyclo-2,2,1-heptane-2 carboxylic acid) caused decreases in glucose and glutamine uptake by cells and reductions in aerobic glycolysis [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Gas chromatography–mass spectrometry analysis showed that silencing LAT1 and LAT3 affected several metabolic pathways including the TCA cycle, lipid, and nucleic acid biosynthesis pathways [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]. Collectively, finding that LAT1 reinforces oncogenic MYC signaling indicates that targeting LAT1 could be a new way to suppress MYC-driven tumors [<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>].</p>
</sec>
<sec id="sec6-ijms-19-02373">
<title>6. NOTCH Signaling Promotes LAT1</title>
<p>The NOTCH signaling pathway is an important upstream regulator of LAT1 signaling in malignant T cells [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. The role of NOTCH in regulating LAT1 signaling during the progression of T cell leukemia was identified using a mouse model of human T-cell acute lymphoblastic leukemia (T-ALL) [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. The mouse model involves targeted PTEN deletion from T cell progenitors in the thymus [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Silencing PTEN in T cells produces malignant T cells that are phenotypically similar to T-ALL in humans [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. As expected, PTEN null T cells exhibited upregulated AKT activity [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. The T-ALL progression correlated with robust increases in nutrient (glucose, glutamine, transferrin, and leucine) uptake by T-ALL cells compared with normal thymocytes [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. The activated AKT was identified as not being sufficient to induce nutrient uptake by T cells, suggesting that pathways other than AKT induce the nutrient uptake by T-ALL cells [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Increases in mTORC1 activity, MYC, HIF1-alpha and NOTCH signaling correlated with increases in nutrient uptake by T-ALL cells [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Inhibiting mTORC1 activity with rapamycin reduced the levels of MYC and HIF1 alpha protein and suppressed glucose uptake by T-ALL cells [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Silencing HIF1 alpha in PTEN null T cells suppressed the progression of T-ALL in mice [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>].</p>
<p>Proteomic analysis identified that levels of the LAT1 protein were higher than the levels of LAT2, LAT3 or LAT4 in T-ALL tumors from mice [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Silencing LAT1 in T-ALL tumors improved the survival of mice compared with mice with LAT1 expressing T-ALL tumors [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Western blot analysis identified reduced mTORC1 activity in LAT1 null T-ALL tumors compared with wild-type T-ALL tumors [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. In terms of signaling, the NOTCH pathway was identified as being important for LAT1 expression in T-ALL cells. For instance, the NOTCH ligand delta-like 1 (DL1) simulated leucine uptake by normal T lymphocytes [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Antagonizing LAT1 suppressed leucine uptake by T cells in response to DL1 [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Inhibiting NOTCH in T-ALL cells with a gamma-secretase inhibitor suppressed the leucine uptake by T-ALL cells [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Suppressing the NOTCH signaling not only suppressed leucine uptake, it also inhibited glucose uptake by T-ALL cells [<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]. Finding that NOTCH supports leucine uptake by T-ALL cells indicates that inhibiting NOTCH could be a new way to suppress leucine signaling to inhibit T-ALL.</p>
</sec>
<sec id="sec7-ijms-19-02373">
<title>7. LAT1 and AHR</title>
<p>LAT1 is overexpressed in breast cancer compared with normal breast tissue, and it is more highly expressed in more advanced cancers, indicating that it is associated with breast cancer progression [<xref ref-type="bibr" rid="B24-ijms-19-02373">24</xref>,<xref ref-type="bibr" rid="B25-ijms-19-02373">25</xref>]. We have recently reported that LAT1 is an aryl hydrocarbon receptor (AHR) target gene and that reducing AHR or LAT1 with short interfering RNA (siRNA) reduces the proliferation of MCF7 and MDA-MB-231 breast cancer cells [<xref ref-type="bibr" rid="B9-ijms-19-02373">9</xref>]. Dioxins are widespread environmental toxicants that bind AHR with high affinity. Dioxins are tumor promoting or tumor suppressing depending on the cancer type and the timing of dioxin exposure [<xref ref-type="bibr" rid="B26-ijms-19-02373">26</xref>]. The compound 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) binds to AHR with high affinity and it is the prototype dioxin. TCDD induces the binding of an AHR complex to intron 2 of the <italic>LAT1</italic> gene that consists of the AHR, AHR nuclear translocator (ARNT) and the transcriptional coactivator p300 [<xref ref-type="bibr" rid="B9-ijms-19-02373">9</xref>]. TCDD-stimulated increases in LAT1 transcription led to increases in leucine uptake by MCF7 breast cancer cells [<xref ref-type="bibr" rid="B9-ijms-19-02373">9</xref>]. In addition to being responsive to exogenous ligands, the AHR has a constitutive activity that modulates gene expression in breast cancer [<xref ref-type="bibr" rid="B27-ijms-19-02373">27</xref>]. In this regard, silencing AHR (in the absence of exogenous AHR ligands) in MCF7 and MDA-MB-231 cells decreased the LAT1 mRNA and LAT1 protein, indicating that constitutive AHR activity promotes the transcription of LAT1 in these breast cancer models [<xref ref-type="bibr" rid="B9-ijms-19-02373">9</xref>]. These results suggest that the regulation of LAT1 by AHR in breast cancer could be important for the progression of this disease.</p>
</sec>
<sec id="sec8-ijms-19-02373">
<title>8. The Role of ATF4 and LAT1 in Prostate Cancer</title>
<p>LAT1 and LAT3 play important roles at different stages of prostate cancer progression. When prostate tumors are responsive to androgen, LAT3 is the dominant leucine transporter because the <italic>LAT3</italic> gene is a direct androgen target gene [<xref ref-type="bibr" rid="B10-ijms-19-02373">10</xref>]. As prostate tumors transition from being hormone responsive to hormone refractory, the expression of LAT3 decreases and the expression of LAT1 increases [<xref ref-type="bibr" rid="B10-ijms-19-02373">10</xref>]. The upregulation of LAT1 in hormone-resistant prostate tumors is due to its transcriptional activation by ATF4 [<xref ref-type="bibr" rid="B10-ijms-19-02373">10</xref>]. Hormone refractory prostate tumors express high levels of ATF4 because they have responded to the amino acid shortage caused by the loss of LAT3 [<xref ref-type="bibr" rid="B10-ijms-19-02373">10</xref>]. In prostate cancer, LAT1 and LAT3 not only contribute to tumor bulk by mediating cancer cell proliferation, they also support metastasis [<xref ref-type="bibr" rid="B11-ijms-19-02373">11</xref>]. Indeed, LAT1 or LAT3 null prostate tumors (PC-3) were smaller and they were less metastatic than wild-type tumors in mice [<xref ref-type="bibr" rid="B11-ijms-19-02373">11</xref>]. Gene expression profiling experiments in prostate cancer cells showed that LAT1- and LAT3-regulated genes were highly associated with cell cycle progression, E2F transcription factors and high-grade metastatic prostate cancer [<xref ref-type="bibr" rid="B11-ijms-19-02373">11</xref>]. Collectively, these results show that LAT1 expression is associated with hormone-resistant prostate cancer and that its expression is induced by ATF4 in this disease [<xref ref-type="bibr" rid="B10-ijms-19-02373">10</xref>,<xref ref-type="bibr" rid="B11-ijms-19-02373">11</xref>].</p>
</sec>
<sec id="sec9-ijms-19-02373">
<title>9. The Role of Glutamine in Supporting LAT1 Activity</title>
<p>Work conducted nearly 10 years ago showed that the cellular uptake of glutamine and leucine activated mTORC1 and suppressed autophagy in Hela cells [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>]. The authors found that glutamine did not activate mTORC1 through a direct mechanism [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>]. Instead, glutamine was transported into Hela cells by SLC1A5, which indirectly supported mTORC1 activity by inducing the activity of LAT1 [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>]. Intracellular glutamine induces LAT1 activity; because LAT1 is an obligate amino acid exchanger that must transport an amino acid out of the cell as it transports leucine into the cell [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>]. In Hela cells, glutamine is the required efflux substrate for LAT1 that induces the LAT1-mediated uptake of leucine [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>]. Glutamine-free cell culture media or preventing glutamine uptake into Hela cells by silencing SLC1A5 inhibits the LAT1-mediated uptake of leucine [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>]. Reductions in LAT1 activity caused concomitant reductions in mTORC1 activity, which in turn increased autophagy [<xref ref-type="bibr" rid="B28-ijms-19-02373">28</xref>].</p>
<p>SLC1A5 maintains LAT1 activity in Hela cells, but not in all cell types. For instance, knocking out SLC1A5 from A549 (lung) or LS174T (colon) cancer cells inhibited glutamine uptake into cells by approximately 70% without inhibiting leucine uptake into cells by LAT1 [<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]. In A549 and LS174T cells, knocking out LAT1 reduced the mTORC1 activity and induced the amino acid stress pathway; however, knocking out SLC1A5 did not affect the activity of these two amino acid responsive pathways [<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]. LAT1 and SLC1A5 are required for the growth of A549 and LS174T tumors in mice [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>,<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]. Western blot analysis of LAT1 null tumors revealed the suppression of mTORC1 signaling and activation of the amino acid stress pathway [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Reductions in mTORC1 activity and increases in the amino acid stress pathway were not evident in the SLC1A5 tumors [<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]. Collectively, these findings indicated that LAT1 and SLC1A5 are important for the growth of lung and colon tumors in mice; however, they support the growth of tumors through different mechanisms [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>,<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]. Mechanistically, LAT1 promoted tumor growth by supporting mTORC1 activity and preventing the activation of amino acid stress pathway [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. The mechanism by which SLC1A5 supported tumor growth does not involve the mTORC1 pathway [<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]. Similar findings were reported in the osteosarcoma 143B cell line, showing that SLC1A5 knockout decreased glutamine transport (by ~60%) without affecting the mTORC1 activity or cell proliferation [<xref ref-type="bibr" rid="B29-ijms-19-02373">29</xref>]. With respect to the osteosarcoma cell study, the authors proposed that glutamine transported into cells by sodium-neutral-amino-acid transporters (SNAT) 1 and 2 maintained mTORC1 and LAT1 activity [<xref ref-type="bibr" rid="B29-ijms-19-02373">29</xref>].</p>
</sec>
<sec id="sec10-ijms-19-02373">
<title>10. LAT1 Inhibitor JPH203</title>
<p>As noted in a previous section, T-ALL in mice is caused by rendering thymic T cells null for PTEN. Gene expression studies identified that the expression of LAT1 increases during the progression of T-ALL in mice [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. T-ALL mouse cell lines also exhibited increases in LAT1 expression compared with normal T cells [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. The higher expression of CD98, which is the LAT1 chaperone protein, was observed in patient-derived T-ALL cells compared with resting or activated peripheral blood lymphocytes from normal patients [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Analyzing the gene expression changes in patient samples (<italic>n</italic> = 72) confirmed that the expression of LAT1 was higher in T-ALL cells compared with normal T lymphocytes [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>].</p>
<p>LAT1 inhibitors decrease the proliferation and viability of T-ALL cells [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Three different LAT1 inhibitors were tested: BCH, <sc>d</sc>-leucine, and JPH203 [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Of the three, JPH203 is the most selective LAT1 inhibitor [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. JPH203 was also the most potent inhibitor of T-ALL cell viability [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. JPH203 reduced the viability of mouse and patient-derived T-ALL cells growing in a cell culture, without being toxic to normal T cells (mouse or human) [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. JPH203 also suppressed T-ALL tumor growth in mice [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. JPH203 did not affect the viability of normal T cells or other types of blood cells (erythrocytes, platelets, bone marrow progenitors) [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Mice dosed with JPH203 did not exhibit reductions in body weight compared with mice dosed with the vehicle [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. The differentiation of normal thymocytes was not disrupted by JPH203 [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. The observed selectivity of JPH203 towards T-ALL cells is presumably because the expression of LAT1 was higher on T-ALL cells compared with normal T cells [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>].</p>
<p>In T-ALL cells, JPH203 induces several signaling pathways [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. JPH203 was a strong inducer of the C/EBP homologous protein (CHOP) and the unfolded protein response (UPR) [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. CHOP is induced in response to endoplasmic reticulum (ER) stress and it promotes apoptosis [<xref ref-type="bibr" rid="B30-ijms-19-02373">30</xref>]. The JPH203 induction of CHOP and UPR was rapid (within 2 h of treatment) and it occurred before the other JPH203 effects [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. The other JPH203 effects occurring after the induction of CHOP were increases in apoptosis, autophagy, and decreases in mTORC1 activation and MYC protein levels [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Starving T-ALL cells of amino acids was sufficient to induce CHOP, which is consistent with how JPH203 would induce CHOP [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. T-ALL cells treated with the UPR inhibitor salubrinal were resistant to JPH203-stimulated increases in CHOP [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Salubrinal also restored proliferation, increased cell viability and suppressed apoptosis of T-ALL cells treated with JPH203 [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Based on these results, the authors proposed that JHP203 induces T-ALL cell death via the induction of CHOP and UPR [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. In support of this postulate, JPH203 fails to induce CHOP in a JHP203 resistant T-ALL cell line [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>].</p>
<p>The authors also tested how combining JPH203 with other cancer drugs affected T-ALL survival in cell culture [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. The findings showed that JPH203 interacted synergistically (strongly) with the mTOR inhibitor rapamycin [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Its interaction with dexamethasone ranged from being primarily synergistic, but also additive, depending on the drug concentration [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. When combined with KU0063794 (a dual mTORC1, mTORC2 inhibitor), PI103 (PI3K inhibitor), doxorubicin or bortezomib (proteasome inhibitor) its effects were drug and concentration-dependent and ranged from antagonism to synergistic [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. Finally, the effect of combining JPH203 with <sc>l</sc>-asparaginase ranged from antagonism (at high drug concentrations), to additive (at middle drug concentrations), to highly synergistic (lowest drug concentrations) [<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]. The effect of JPH203 on other cancer cell types have been tested, and the reported effects have shown that it inhibits the cell cycle and/or promoted apoptosis in cancer cells. Specifically, JPH203 inhibits osteosarcoma [<xref ref-type="bibr" rid="B31-ijms-19-02373">31</xref>], cholangiocarcinoma [<xref ref-type="bibr" rid="B32-ijms-19-02373">32</xref>], human thymic carcinoma cells [<xref ref-type="bibr" rid="B33-ijms-19-02373">33</xref>], and lung cancer cells [<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>]. Thus, these reports indicate that JPH203 anti-cancer effects could be applicable to other cancers that express LAT1 and that it is not toxic toward normal cells.</p>
</sec>
<sec id="sec11-ijms-19-02373">
<title>11. Conclusions</title>
<p>From all apparent evidence, the LAT1/amino acid signaling pathway in cancer cells is an effective target for cancer therapy. There is still a need for uncovering new ways to target the cancer-specific expression of LAT1, given that LAT1 is important for proper brain function and for the expansion of normal T cells [<xref ref-type="bibr" rid="B34-ijms-19-02373">34</xref>,<xref ref-type="bibr" rid="B35-ijms-19-02373">35</xref>]. The possibility that targeting LAT1 stimulates the compensatory upregulation of a different LAT transporter (i.e., LAT2, LAT3, or LAT4), or a different transporter system (i.e., SNAT amino acid transporters [<xref ref-type="bibr" rid="B29-ijms-19-02373">29</xref>]) in certain cancers also warrants investigation. There is also a need to identify specific biomarkers to predict sensitivity or resistance to LAT1 targeting therapies. Thus, collectively, the LAT1-leucine-signaling pathway in cancer and its therapeutic targeting is still a very active area of research.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>T.B.S. and S.A. wrote the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This work was funded by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM121299, the WV-INBRE grant (P20GM103434) and The Edwards Foundation, Inc. Cancer-Related Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflicts of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-19-02373">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosios</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Hecht</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Danai</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Rathmell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Steinhauser</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Manalis</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Vander Heiden</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells</article-title>
<source/>Dev. Cell
          <year>2016</year>
<volume>36</volume>
<fpage>540</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2016.02.012</pub-id>
<pub-id pub-id-type="pmid">26954548</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-19-02373">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia</article-title>
<source/>Am. J. Cancer Res.
          <year>2015</year>
<volume>5</volume>
<fpage>1281</fpage>
<lpage>1294</lpage>
<pub-id pub-id-type="pmid">26101697</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-19-02373">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cormerais</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Giuliano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>LeFloch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Front</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Durivault</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tambutte</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Massard</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>de la Ballina</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wempe</surname>
<given-names>M.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth</article-title>
<source/>Cancer Res.
          <year>2016</year>
<volume>76</volume>
<fpage>4481</fpage>
<lpage>4492</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3376</pub-id>
<pub-id pub-id-type="pmid">27302165</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-19-02373">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cormerais</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Massard</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Vucetic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giuliano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tambutte</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Durivault</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vial</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wempe</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Parks</surname>
<given-names>S.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>2877</fpage>
<lpage>2887</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA117.001342</pub-id>
<pub-id pub-id-type="pmid">29326164</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-19-02373">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dann</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Ryskin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barsotti</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Golas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hosselet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lemon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karnoub</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2</article-title>
<source/>EMBO J.
          <year>2015</year>
<volume>34</volume>
<fpage>1773</fpage>
<lpage>1785</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201488166</pub-id>
<pub-id pub-id-type="pmid">25979827</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-19-02373">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qing</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis</article-title>
<source/>Cell Rep.
          <year>2017</year>
<volume>21</volume>
<fpage>3819</fpage>
<lpage>3832</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.002</pub-id>
<pub-id pub-id-type="pmid">29281830</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-19-02373">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grzes</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Swamy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hukelmann</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Emslie</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Cantrell</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy</article-title>
<source/>Leukemia
          <year>2017</year>
<volume>31</volume>
<fpage>2771</fpage>
<lpage>2779</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2017.160</pub-id>
<pub-id pub-id-type="pmid">28546582</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-19-02373">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosilio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nebout</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Imbert</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Griessinger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Neffati</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Benadiba</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hagenbeek</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Spits</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reverso</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ambrosetti</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>L-type amino-acid transporter 1 (LAT1): A therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia</article-title>
<source/>Leukemia
          <year>2015</year>
<volume>29</volume>
<fpage>1253</fpage>
<lpage>1266</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2014.338</pub-id>
<pub-id pub-id-type="pmid">25482130</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-19-02373">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomblin</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Primerano</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Chaudhry</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Denvir</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salisbury</surname>
<given-names>T.B.</given-names>
</name>
</person-group>
<article-title>Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells</article-title>
<source/>Biochem. Pharmacol.
          <year>2016</year>
<volume>106</volume>
<fpage>94</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2016.02.020</pub-id>
<pub-id pub-id-type="pmid">26944194</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-19-02373">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tiffen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thoeng</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Minhas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lehman</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Hendy</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>C.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression</article-title>
<source/>Cancer Res.
          <year>2011</year>
<volume>71</volume>
<fpage>7525</fpage>
<lpage>7536</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1821</pub-id>
<pub-id pub-id-type="pmid">22007000</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-19-02373">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tiffen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Lehman</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fazli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Metierre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gleave</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting amino acid transport in metastatic castration-resistant prostate cancer: Effects on cell cycle, cell growth, and tumor development</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2013</year>
<volume>105</volume>
<fpage>1463</fpage>
<lpage>1473</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/djt241</pub-id>
<pub-id pub-id-type="pmid">24052624</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-19-02373">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saxton</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>mTOR Signaling in Growth, Metabolism, and Disease</article-title>
<source/>Cell
          <year>2017</year>
<volume>169</volume>
<fpage>361</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.03.035</pub-id>
<pub-id pub-id-type="pmid">28388417</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-19-02373">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfson</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Chantranupong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Saxton</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Scaria</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Cantor</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Sestrin2 is a leucine sensor for the mTORC1 pathway</article-title>
<source/>Science (New York, N.Y.)
          <year>2016</year>
<volume>351</volume>
<fpage>43</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1126/science.aab2674</pub-id>
<pub-id pub-id-type="pmid">26449471</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-19-02373">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fallahi Sichani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Coordination of the leucine-sensing Rag GTPase cycle by leucyl-tRNA synthetase in the mTORC1 signaling pathway</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2018</year>
<volume>115</volume>
<fpage>E5279</fpage>
<lpage>E5288</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1801287115</pub-id>
<pub-id pub-id-type="pmid">29784813</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-19-02373">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sancak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bar-Peled</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zoncu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Markhard</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Nada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids</article-title>
<source/>Cell
          <year>2010</year>
<volume>141</volume>
<fpage>290</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2010.02.024</pub-id>
<pub-id pub-id-type="pmid">20381137</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-19-02373">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway</article-title>
<source/>Cell
          <year>2012</year>
<volume>149</volume>
<fpage>410</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.02.044</pub-id>
<pub-id pub-id-type="pmid">22424946</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-19-02373">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milkereit</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Persaud</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vanoaica</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guetg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rotin</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>7250</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms8250</pub-id>
<pub-id pub-id-type="pmid">25998567</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-19-02373">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoncu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bar-Peled</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Efeyan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sancak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase</article-title>
<source/>Science (New York, N.Y.)
          <year>2011</year>
<volume>334</volume>
<fpage>678</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="doi">10.1126/science.1207056</pub-id>
<pub-id pub-id-type="pmid">22053050</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-19-02373">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>41282</fpage>
<lpage>41293</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.17176</pub-id>
<pub-id pub-id-type="pmid">28476037</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-19-02373">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>LAPTM4B Predicts Axillary Lymph Node Metastasis in Breast Cancer and Promotes Breast Cancer Cell Aggressiveness in Vitro</article-title>
<source/>Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.
          <year>2017</year>
<volume>41</volume>
<fpage>1072</fpage>
<lpage>1082</lpage>
<pub-id pub-id-type="doi">10.1159/000464115</pub-id>
<pub-id pub-id-type="pmid">28245476</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-19-02373">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ip</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sethi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>CD98 signals controlling tumorigenesis</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <year>2016</year>
<volume>81</volume>
<fpage>148</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2016.11.005</pub-id>
<pub-id pub-id-type="pmid">27840151</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-19-02373">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Targeting EZH2 for cancer therapy: Progress and perspective</article-title>
<source/>Curr. Protein Pept. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>559</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.2174/1389203716666150409100233</pub-id>
<pub-id pub-id-type="pmid">25854924</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-19-02373">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goetzman</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Prochownik</surname>
<given-names>E.V.</given-names>
</name>
</person-group>
<article-title>The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues</article-title>
<source/>Front. Endocrinol.
          <year>2018</year>
<volume>9</volume>
<fpage>129</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00129</pub-id>
<pub-id pub-id-type="pmid">29706933</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-19-02373">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Ansari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Craze</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Miligy</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Diez-Rodriguez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nolan</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>I.O.</given-names>
</name>
<name>
<surname>Rakha</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours</article-title>
<source/>Breast Cancer Res. BCR
          <year>2018</year>
<volume>20</volume>
<fpage>21</fpage>
<pub-id pub-id-type="doi">10.1186/s13058-018-0946-6</pub-id>
<pub-id pub-id-type="pmid">29566741</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-19-02373">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartlett</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Seitz</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>B.Z.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kunkler</surname>
<given-names>I.H.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>F.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy</article-title>
<source/>Breast Cancer Res. BCR
          <year>2010</year>
<volume>12</volume>
<fpage>R47</fpage>
<pub-id pub-id-type="doi">10.1186/bcr2604</pub-id>
<pub-id pub-id-type="pmid">20615243</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-19-02373">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>U.H.</given-names>
</name>
</person-group>
<article-title>Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target</article-title>
<source/>Toxicol. Sci. An Off. J. Soc. Toxicol.
          <year>2013</year>
<volume>135</volume>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1093/toxsci/kft128</pub-id>
<pub-id pub-id-type="pmid">23771949</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-19-02373">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salisbury</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Tomblin</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Primerano</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Boskovic</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mehmi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Santanam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hurn</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>G.Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Endogenous aryl hydrocarbon receptor promotes basal and inducible expression of tumor necrosis factor target genes in MCF-7 cancer cells</article-title>
<source/>Biochem. Pharmacol.
          <year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.bcp.2014.06.015</pub-id>
<pub-id pub-id-type="pmid">24971714</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-19-02373">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicklin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Triantafellow</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nyfeler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hild</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bidirectional transport of amino acids regulates mTOR and autophagy</article-title>
<source/>Cell
          <year>2009</year>
<volume>136</volume>
<fpage>521</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.11.044</pub-id>
<pub-id pub-id-type="pmid">19203585</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-19-02373">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rahimi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Broer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells</article-title>
<source/>J. Biol. Chem.
          <year>2016</year>
<volume>291</volume>
<fpage>13194</fpage>
<lpage>13205</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.700534</pub-id>
<pub-id pub-id-type="pmid">27129276</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-19-02373">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Naik</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Braunstein</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Transcription Factor C/EBP Homologous Protein in Health and Diseases</article-title>
<source/>Front. Immunol.
          <year>2017</year>
<volume>8</volume>
<fpage>1612</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.01612</pub-id>
<pub-id pub-id-type="pmid">29230213</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-19-02373">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wempe</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells</article-title>
<source/>Korean J. Physiol. Pharmacol. Off. J. Korean Physiol. Soc. Korean Soc. Pharmacol.
          <year>2017</year>
<volume>21</volume>
<fpage>599</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.4196/kjpp.2017.21.6.599</pub-id>
<pub-id pub-id-type="pmid">29200902</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-19-02373">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yothaisong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dokduang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Anzai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Namwat</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yongvanit</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sangkhamanon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jutabha</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Loilome</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment</article-title>
<source/>Tumour Biol. J. Int. Soc. Oncodev. Biol. Med.
          <year>2017</year>
<volume>39</volume>
<fpage>1010428317694545</fpage>
<pub-id pub-id-type="doi">10.1177/1010428317694545</pub-id>
<pub-id pub-id-type="pmid">28347255</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-19-02373">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jutabha</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Supak</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ouchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chida</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Anzai</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells</article-title>
<source/>J. Pharmacol. Sci.
          <year>2016</year>
<volume>132</volume>
<fpage>201</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.jphs.2016.07.006</pub-id>
<pub-id pub-id-type="pmid">27567475</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-19-02373">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarlungeanu</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Deliu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dotter</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Kara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Janiesch</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Scalise</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galluccio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tesulov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sonmez</surname>
<given-names>F.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder</article-title>
<source/>Cell
          <year>2016</year>
<volume>167</volume>
<fpage>1481</fpage>
<lpage>1494</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.11.013</pub-id>
<pub-id pub-id-type="pmid">27912058</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-19-02373">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinclair</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Rolf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Emslie</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.B.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Cantrell</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation</article-title>
<source/>Nat. Immunol.
          <year>2013</year>
<volume>14</volume>
<fpage>500</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.1038/ni.2556</pub-id>
<pub-id pub-id-type="pmid">23525088</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="ijms-19-02373-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-19-02373-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>The cancer-specific regulation and function of L-Type Amino Acid Transporter 1 (LAT1).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cancer Type</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cell Line(s)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Upstream Regulators of LAT1</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Downstream Effects of LAT1</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lung, Colon</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A549, LS174T</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 silencing led to smaller tumors in mice, reductions in leucine uptake, reductions in mTORC1 activity, amino acid stress, decreases in proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B3-ijms-19-02373">3</xref>,<xref ref-type="bibr" rid="B4-ijms-19-02373">4</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lung</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NCI-H1299</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EZH2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 silencing led to smaller tumors in mice, decreases in EZH2 expression and activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B5-ijms-19-02373">5</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glioblastoma, Burkitt’s Lymphoma </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Daudi, BE-2C, SHEP MYCN-ER, P493</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MYC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 silencing led to reductions in MYC translation, decreases in leucine uptake, smaller tumors in mice, decreases in proliferation, altered cancer cell metabolism, many gene expression changes</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B6-ijms-19-02373">6</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">T-cell acute lymphoblastic leukemia (T-ALL)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse model of T-ALL, patient-derived T-ALL cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NOTCH</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 silencing led to the inhibition of T-ALL progression in vivo </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B7-ijms-19-02373">7</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">T-cell acute lymphoblastic leukemia (T-ALL)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse model of T-ALL, patient-derived T-ALL cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">JPH203 (LAT1 antagonist)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 antagonism by JPH203 led to decreases in proliferation, increases in apoptosis, smaller T-ALL tumors in mice, increases in CHOP and ER stress, apoptosis, and autophagy and decreases in mTORC1 activity </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B8-ijms-19-02373">8</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Breast</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MDA-MB-231, MCF7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TCDD, AHR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 silencing led to decreases in proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B9-ijms-19-02373">9</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Prostate</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PC-3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ATF4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LAT1 silencing led to smaller tumors in mice, decreases in metastasis in mice, reductions in leucine uptake, reductions in mTORC1 activity, amino acid stress, decreases in proliferation, increases in apoptosis, many gene expression changes</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B10-ijms-19-02373">10</xref>,<xref ref-type="bibr" rid="B11-ijms-19-02373">11</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>